全文获取类型
收费全文 | 900182篇 |
免费 | 62361篇 |
国内免费 | 2333篇 |
专业分类
耳鼻咽喉 | 12476篇 |
儿科学 | 28698篇 |
妇产科学 | 26147篇 |
基础医学 | 126626篇 |
口腔科学 | 24686篇 |
临床医学 | 74788篇 |
内科学 | 183222篇 |
皮肤病学 | 19112篇 |
神经病学 | 71405篇 |
特种医学 | 36474篇 |
外国民族医学 | 336篇 |
外科学 | 142143篇 |
综合类 | 19031篇 |
一般理论 | 247篇 |
预防医学 | 64601篇 |
眼科学 | 20157篇 |
药学 | 63816篇 |
中国医学 | 1799篇 |
肿瘤学 | 49112篇 |
出版年
2018年 | 9056篇 |
2017年 | 7168篇 |
2016年 | 7680篇 |
2015年 | 8727篇 |
2014年 | 12374篇 |
2013年 | 19216篇 |
2012年 | 25666篇 |
2011年 | 27279篇 |
2010年 | 16578篇 |
2009年 | 15788篇 |
2008年 | 26143篇 |
2007年 | 27750篇 |
2006年 | 27934篇 |
2005年 | 27472篇 |
2004年 | 26312篇 |
2003年 | 25487篇 |
2002年 | 25073篇 |
2001年 | 41370篇 |
2000年 | 42581篇 |
1999年 | 36288篇 |
1998年 | 9975篇 |
1997年 | 9158篇 |
1996年 | 9084篇 |
1995年 | 8448篇 |
1994年 | 8086篇 |
1993年 | 7591篇 |
1992年 | 28215篇 |
1991年 | 27009篇 |
1990年 | 26429篇 |
1989年 | 25357篇 |
1988年 | 23565篇 |
1987年 | 23187篇 |
1986年 | 22259篇 |
1985年 | 21164篇 |
1984年 | 15818篇 |
1983年 | 13487篇 |
1982年 | 8087篇 |
1979年 | 14597篇 |
1978年 | 10211篇 |
1977年 | 8628篇 |
1976年 | 8149篇 |
1975年 | 8962篇 |
1974年 | 10697篇 |
1973年 | 10185篇 |
1972年 | 9662篇 |
1971年 | 8920篇 |
1970年 | 8586篇 |
1969年 | 8026篇 |
1968年 | 7684篇 |
1967年 | 7086篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
Wojciech Szychta M.D. Ph.D. Gheorghe Cerin M.D. Ph.D. F.E.S.C. Bogdan Adrian Popa M.D. Armienti Felice M.D. Guido Lanzillo M.D. Ph.D. Marco Diena M.D. Grzegorz Opolski M.D. Ph.D. F.E.S.C. 《Echocardiography (Mount Kisco, N.Y.)》2015,32(6):1040-1043
Sinus venosus atrial septal defect (SV‐ASD) usually coexists with partial anomalous pulmonary vein connection (PAPVC). It is a difficult diagnosis in transthoracic echocardiography (TTE) due to eccentric position of defects. We present a rare case of atypical anatomical variation in PAPVC, which was never described before. Two right pulmonary veins drained into superior vena cava, which overrode SV‐ASD and interatrial septum, a third pulmonary vein into the right atrium. Complete diagnosis could not be set after TTE, nor transesophageal echocardiography, whereas angio‐CT was finally conclusive. This diagnostic approach allowed the surgical planning. 相似文献
3.
4.
5.
6.
7.
8.
9.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
10.